A detailed history of Pacer Advisors, Inc. transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Pacer Advisors, Inc. holds 2,586,828 shares of COLL stock, worth $83.3 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
2,586,828
Previous 2,174,718 18.95%
Holding current value
$83.3 Million
Previous $66.9 Million 50.02%
% of portfolio
0.26%
Previous 0.21%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$31.23 - $40.91 $12.9 Million - $16.9 Million
412,110 Added 18.95%
2,586,828 $100 Million
Q4 2023

Jan 16, 2024

BUY
$21.16 - $30.8 $18.7 Million - $27.2 Million
883,380 Added 68.41%
2,174,718 $66.9 Million
Q3 2023

Nov 13, 2023

BUY
$21.23 - $24.28 $10.9 Million - $12.4 Million
511,692 Added 65.63%
1,291,338 $28.9 Million
Q2 2023

Jul 12, 2023

BUY
$21.06 - $24.0 $7.09 Million - $8.09 Million
336,879 Added 76.08%
779,646 $16.8 Million
Q1 2023

May 02, 2023

BUY
$23.0 - $29.88 $3.25 Million - $4.23 Million
141,458 Added 46.95%
442,767 $10.6 Million
Q4 2022

Feb 06, 2023

BUY
$16.14 - $23.55 $4.86 Million - $7.1 Million
301,309 New
301,309 $6.99 Million
Q2 2022

Aug 12, 2022

SELL
$14.22 - $20.88 $3.14 Million - $4.61 Million
-220,982 Closed
0 $0
Q1 2022

Apr 05, 2022

BUY
$17.2 - $22.5 $1.29 Million - $1.69 Million
75,090 Added 51.47%
220,982 $4.5 Million
Q4 2021

Feb 03, 2022

BUY
$17.5 - $21.35 $692,265 - $844,563
39,558 Added 37.2%
145,892 $2.73 Million
Q3 2021

Oct 15, 2021

BUY
$17.75 - $25.39 $282,793 - $404,513
15,932 Added 17.62%
106,334 $2.1 Million
Q2 2021

Jul 21, 2021

BUY
$21.74 - $25.28 $1.97 Million - $2.29 Million
90,402 New
90,402 $2.14 Million

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.1B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.